82 related articles for article (PubMed ID: 21597687)
1. Clinical-evaluation of serum basic fetoprotein as a marker in urogenital malignant-tumors.
Gotoh A; Harada K; Gohji K; Arakawa S; Kamidono S
Oncol Rep; 1995 Jan; 2(1):49-53. PubMed ID: 21597687
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation on an enzyme immunoassay kit for basic fetoprotein (BFP). (2) Comparison and combination of BFP with other tumor markers].
Ishii M; Hattori N; Kato T; Mochizuki M; Kamidono S; Sawabu N; Kawada Y; Kawai T; Abe O; Ohkura H
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2115-23. PubMed ID: 2456040
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of serum basic fetoprotein in patients with urogenital malignancies and renal transplantation].
Seguchi T; Sugao H; Takahara S; Nakano E; Ishibashi M; Sonoda T
Hinyokika Kiyo; 1991 Nov; 37(11):1475-9. PubMed ID: 1722636
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation on an enzyme immunoassay kit for basic fetoprotein (BFP). (1) Clinical usefulness of BFP].
Ishii M; Hattori N; Kato T; Mochizuki M; Kamidono S; Sawabu N; Kawada Y; Kawai T; Abe O; Ohkura H
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2107-13. PubMed ID: 2456039
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of tumor markers in prostatic cancer].
Ishihara Y; Fukagai T; Ohta K; Hiromoto Y; Hiramori M; Torii T; Higaki Y; Imamura K
Hinyokika Kiyo; 1990 Apr; 36(4):425-31. PubMed ID: 1696063
[TBL] [Abstract][Full Text] [Related]
6. [Significance of tumor markers in the treatment of urological malignancies].
Akaza H; Kameyama S; Aso Y
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3034-40. PubMed ID: 2445294
[TBL] [Abstract][Full Text] [Related]
7. [Molecular staging of testicular cancer using polymerase chain reaction of the testicular cancer-specific genes].
Nonomura N; Imazu T; Harada Y; Nozawa M; Ono Y; Fukui T; Nishimura K; Okuyama A
Hinyokika Kiyo; 1999 Aug; 45(8):593-7. PubMed ID: 10500969
[TBL] [Abstract][Full Text] [Related]
8. [The clinical significance of serum tissue polypeptide antigen as a tumor marker for urogenital carcinomas--a comparison with other tumor markers in patients with renal cell carcinoma and prostatic carcinoma].
Yamazaki K; Kumamoto Y; Tsukamoto T; Umehara T; Ohmura K
Hinyokika Kiyo; 1987 Oct; 33(10):1581-9. PubMed ID: 2451408
[TBL] [Abstract][Full Text] [Related]
9. Serum basic fetoprotein in patients with renal cell carcinoma.
Gohji K; Ishii M; Nagata H; Matsumoto O; Kamidono S
Cancer; 1990 Mar; 65(6):1405-11. PubMed ID: 1689608
[TBL] [Abstract][Full Text] [Related]
10. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
11. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
12. Urinary basic fetoprotein in the diagnosis and follow-up of patients with urothelial carcinoma.
Kigure T; Wakayama Y; Satoh Y; Fujieda N; Yoshida K; Harada T
Cancer; 1996 Apr; 77(8):1529-34. PubMed ID: 8608539
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
[TBL] [Abstract][Full Text] [Related]
14. Lectin-reactive alpha-fetoprotein as a marker for testicular tumor activity.
Kawai K; Kojima T; Miyanaga N; Hattori K; Hinotsu S; Shimazui T; Akaza H
Int J Urol; 2005 Mar; 12(3):284-9. PubMed ID: 15828957
[TBL] [Abstract][Full Text] [Related]
15. [Tumor markers of hepatocellular carcinoma with special reference to diagnostic efficacy of combination of these markers and relation to its stages].
Sawabu N; Wakabayashi T; Ozaki K; Toya D; Yoneshima M
Gan No Rinsho; 1983 May; 29(6):672-7. PubMed ID: 6192267
[TBL] [Abstract][Full Text] [Related]
16. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
17. [Clinical investigation of basic fetoprotein (BFP) and carcinoembryonic antigen (CEA) in stomach cancer and lung cancer].
Kanda Y; Ishii M
Gan No Rinsho; 1985 May; 31(6 Suppl):600-5. PubMed ID: 2411961
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
20. [Tumor markers--personal experience. The use of tumor markers for cancer of digestive organs].
Ishii M
Gan To Kagaku Ryoho; 1991 May; 18(6):1059-65. PubMed ID: 1709347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
